Figure 1. Summary of Par-4 protein and its cleavage in ovarian and endometrial cancer cells upon cisplatin treatment.

A. Schematic of Par-4 domains including the caspase-3 cleavage site location. B. Histogram presenting the low level of alteration of Par-4 gene (PAWR) occurring in various cancer cell lines. C. Ovarian cancer cell lines (A2780-A2780CP) and endometrial cancer cell lines (Ishikawa and Hec-1a) were treated with 10-20μM Cisplatin for 24h. The level of Par-4 and its cleaved fragment were determined in treated cells using western blot analysis. GAPDH was used as a loading control. Results shown are representative of three independent experiments.